Literature DB >> 2233716

Functional analysis of c-Myb protein in T-lymphocytic cell lines shows that it trans-activates the c-myc promoter.

J L Evans1, T L Moore, W M Kuehl, T Bender, J P Ting.   

Abstract

The function of c-Myb protein was revealed by transfecting an expression vector containing the entire c-Myb protein-coding sequence into the murine CTLL-2 T-cell line. Expressions of high levels of c-Myb protein did not alter the expression of several T-cell markers, c-fos mRNA expression, responses to interleukin-2, and growth characteristics of these cells. Interestingly, expression of the c-myc gene was drastically increased in this clone. Further, the c-myb expression plasmid, but not a frameshift mutant of c-myb, enhanced the expression of a hybrid construct of c-myc promoter linked to a reporter gene by 8- to 14-fold. These results demonstrate a role of c-Myb protein in c-myc gene expression.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2233716      PMCID: PMC361348          DOI: 10.1128/mcb.10.11.5747-5752.1990

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  55 in total

1.  c-myc products trans-activate the adenovirus E4 promoter in EC stem cells by using the same target sequence as E1A products.

Authors:  R Onclercq; P Gilardi; A Lavenu; C Cremisi
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

2.  Nucleotide sequence of the retroviral leukemia gene v-myb and its cellular progenitor c-myb: the architecture of a transduced oncogene.

Authors:  K H Klempnauer; T J Gonda; J M Bishop
Journal:  Cell       Date:  1982-12       Impact factor: 41.582

3.  Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter.

Authors:  P J Southern; P Berg
Journal:  J Mol Appl Genet       Date:  1982

4.  Homogeneously staining chromosomal regions contain amplified copies of an abundantly expressed cellular oncogene (c-myc) in malignant neuroendocrine cells from a human colon carcinoma.

Authors:  K Alitalo; M Schwab; C C Lin; H E Varmus; J M Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

5.  Cytoplasmic dot hybridization. Simple analysis of relative mRNA levels in multiple small cell or tissue samples.

Authors:  B A White; F C Bancroft
Journal:  J Biol Chem       Date:  1982-08-10       Impact factor: 5.157

6.  FBJ murine osteosarcoma virus: identification and molecular cloning of biologically active proviral DNA.

Authors:  T Curran; G Peters; C Van Beveren; N M Teich; I M Verma
Journal:  J Virol       Date:  1982-11       Impact factor: 5.103

7.  DNA rearrangement and altered RNA expression of the c-myb oncogene in mouse plasmacytoid lymphosarcomas.

Authors:  J F Mushinski; M Potter; S R Bauer; E P Reddy
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

8.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.

Authors:  C M Gorman; L F Moffat; B H Howard
Journal:  Mol Cell Biol       Date:  1982-09       Impact factor: 4.272

9.  Abnormalities induced by the mutant gene Ipr: expansion of a unique lymphocyte subset.

Authors:  H C Morse; W F Davidson; R A Yetter; E D Murphy; J B Roths; R L Coffman
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

10.  A monoclonal antibody that recognizes B cells and B cell precursors in mice.

Authors:  R L Coffman; I L Weissman
Journal:  J Exp Med       Date:  1981-02-01       Impact factor: 14.307

View more
  26 in total

1.  Deregulated c-myb disrupts interleukin-6- or leukemia inhibitory factor-induced myeloid differentiation prior to c-myc: role in leukemogenesis.

Authors:  M Selvakumaran; D A Liebermann; B Hoffman-Liebermann
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

2.  The cellular oncogene c-myb can interact synergistically with the Epstein-Barr virus BZLF1 transactivator in lymphoid cells.

Authors:  S C Kenney; E Holley-Guthrie; E B Quinlivan; D Gutsch; Q Zhang; T Bender; J F Giot; A Sergeant
Journal:  Mol Cell Biol       Date:  1992-01       Impact factor: 4.272

3.  The cellular proto-oncogene product Myb acts as transcriptional activator of the long terminal repeat of human T-lymphotropic virus type I.

Authors:  P Dasgupta; C D Reddy; P Saikumar; E P Reddy
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

Review 4.  Transcriptional regulation during myelopoiesis.

Authors:  N Lenny; J J Westendorf; S W Hiebert
Journal:  Mol Biol Rep       Date:  1997-08       Impact factor: 2.316

5.  Myb controls G(2)/M progression by inducing cyclin B expression in the Drosophila eye imaginal disc.

Authors:  Masahiro Okada; Hiroshi Akimaru; De-Xing Hou; Tomomi Takahashi; Shunsuke Ishii
Journal:  EMBO J       Date:  2002-02-15       Impact factor: 11.598

6.  Regulation of the resident chromosomal copy of c-myc by c-Myb is involved in myeloid leukemogenesis.

Authors:  M Schmidt; V Nazarov; L Stevens; R Watson; L Wolff
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

7.  Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression.

Authors:  K S Lee; M Buck; K Houglum; M Chojkier
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

8.  Only the DNA binding and transactivation domains of c-Myb are required to block terminal differentiation of murine erythroleukemia cells.

Authors:  A E Cuddihy; L A Brents; N Aziz; T P Bender; W M Kuehl
Journal:  Mol Cell Biol       Date:  1993-06       Impact factor: 4.272

9.  Functional and physical associations between NF-kappa B and C/EBP family members: a Rel domain-bZIP interaction.

Authors:  B Stein; P C Cogswell; A S Baldwin
Journal:  Mol Cell Biol       Date:  1993-07       Impact factor: 4.272

10.  Regulation of cyst wall protein promoters by Myb2 in Giardia lamblia.

Authors:  Yu-Chang Huang; Li-Hsin Su; Gilbert A Lee; Pei-Wei Chiu; Chao-Cheng Cho; Jeng-You Wu; Chin-Hung Sun
Journal:  J Biol Chem       Date:  2008-09-03       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.